Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 September;63(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 September;63(3):278-83

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 September;63(3):278-83

DOI: 10.23736/S1824-4785.16.02877-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

The effects of androgen deprivation therapy on the 18F-Chcoline uptake in prostate cancer patients undergoing neoadjuvant treatment

Laura EVANGELISTA 1 , Fabio ZATTONI 2, Andrea GUTTILLA 2, Umberto BASSO 3, Filiberto ZATTONI 2

1 Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; 2 Department of Oncological and Surgical Sciences, Clinic of Urology, University of Padua, Padua, Italy; 3 Unit of Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy


PDF


BACKGROUND: The aim of the present study was to evaluate how neoadjuvant androgen deprivation therapy (ADT) can impact 18F-choline uptake in primary prostate cancer (PC) and its metastases before radical prostatectomy (RP) or radiation therapy (RT).
METHODS: We retrospectively reviewed images of 79 PC patients undergoing 18F-choline PET/CT before RP or RT. Based on concomitant administration of neoadjuvant ADT at the time of 18F-choline PET/CT, patients were subdivided into naïve group (Group 1) and neoadjuvant ADT group (Group 2). PET/CT results, SUVmax and metabolic tumor volume (MTV) for each site were re-assessed by two nuclear medicine physicians with more than 5 years of experience. A chi-square and a U-Mann Whitney test were used to compare the two groups.
RESULTS: Sixty-two patients were included in Group 1, while 17 in Group 2. PET/CT was positive in all patients, in particular: 54 had a significant uptake in prostate alone, 12 in prostate plus lymph nodes (LN), 4 in prostate plus LN and bone, 3 in prostate plus bone and 6 in prostate plus other organs (such as lung or thyroid). PET/CT was more frequently positive in a different site, outside the prostate, in Group 1 as compared to Group 2 (P<0.001). Conversely, median SUVmax and MTV in the prostate resulted significantly lower in Group 2 than in Group 1 (5.34 vs. 7.72 and 3.66 vs. 6.86 cm3, respectively; both P<0.05).
CONCLUSIONS: PET/CT could have an important role in prostate cancer staging before primary treatment; however, before imaging, hormonal therapy status should be carefully evaluated.


KEY WORDS: Prostatic neoplasms; Androgen antagonists; Positron-emission tomography; Fluoromethylcholine

top of page